BPC-157 10mg Synthetic research peptide (10mg vial)
The limited efficacy of even potent immunosuppression in the later stages (Wolinsky et al., 2020) is likely due to a waning of the acute/adaptive auto-immune component, rather than restricted access of biologicals to the CNS (as an example of adequate access of biologicals to the brain, systemic administration of anti-amyloid antibodies in Alzheimers has now been shown to be effective at reducing amyloid load (Jucker and Walker, 2023
thanks MINECO for a Juan de la Cierva Incorporacion fellowship (IJC2020-045506-I)
The surge in demand for GLP-1 agonists (semaglutide and tirzepatide) has put peptide therapy into mainstream conversation but many patients arrive without a clear picture of how GLP-1s compare to other peptides, or what a supervised program actually looks like
Korczowska-cka I, Sowikowski B, Piekut T, Hura M, Banaszek N, Szymanowicz O, et al
thickener: sodium alginate